Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
Nuvalent (NUVL) is back in focus after fresh clinical and regulatory updates for its cancer pipeline, including FDA review progress for zidesamtinib and new trial data to be spotlighted at major oncology meetings. See our latest analysis for Nuvalent. The latest FDA milestones and conference data sit alongside a 12.35% 1 month share price return and a very large 3 year total shareholder return, suggesting momentum around Nuvalent's cancer pipeline and shifting expectations for future risk and opportunity. If you are looking beyond a single name in oncology, this is a good moment to check out other potential healthcare AI opportunities using the 34 healthcare AI stocks With Nuvalent sharing fresh data, an FDA review underway and the share price already up 46% over 12 months, are you looking at an underappreciated oncology pipeline, or has the market already priced in future growth? DCF valuation points to a wide gap between price and fair value Our DCF model estimates Nuva
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual MeetingPR Newswire
- Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.MarketBeat
- New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]Yahoo! Finance
- New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026PR Newswire
NUVL
Earnings
- 2/26/26 - Miss
NUVL
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- NUVL's page on the SEC website